atorvastatin has been researched along with pravastatin in 573 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (3.84) | 18.2507 |
| 2000's | 373 (65.10) | 29.6817 |
| 2010's | 155 (27.05) | 24.3611 |
| 2020's | 23 (4.01) | 2.80 |
| Authors | Studies |
|---|---|
| Hsiang, B; Kirchgessner, TG; Sasseville, V; Wang, Z; Wu, Y; Yang, WP; Zhu, Y | 1 |
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Chiba, K; Hosokawa, M; Kameyama, Y; Kobayashi, K; Yamashita, K | 1 |
| Carbonell, T; Freire, E | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Caspers, N; Choi, C; Dillon, L; Hanselman, JC; Harris, MS; Hutchings, R; Kowala, M; Larsen, SD; Lin, Z; Lu, GH; Park, W; Pavlovsky, A; Pfefferkorn, JA; Robertson, A; Sekerke, C; Tait, BD | 1 |
| Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
| Ahmad, S; Barrish, JC; Bird, E; Bisaha, S; Blanar, MA; Chang, M; Chen, BC; Chen, X; Cuff, CA; Darienzo, CJ; Giancarli, M; Harrity, T; Huang, C; Janovitz, E; Kennedy, LJ; Li, T; Madsen, CS; Monshizadegan, H; Ngu, K; Nguyen-Tran, V; Reeves, RA; Robl, JA; Ryan, CS; Search, D; Setters, R; Sitkoff, D; Stein, PD; Yin, X; Zahler, R; Zhang, R; Zhao, R; Zhuang, S | 1 |
| Bienvenu, AL; Picot, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bracha, AL; Huang, S; Ingber, DE; Ramanathan, A; Schreiber, SL | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bak Mueller, S; Bocan, TM; Dehart, P; Ferguson, E; Krause, BR; McNally, W; Newton, RS; Roth, BD; Sliskovic, DR; Uhlendorf, PD | 1 |
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Bertolini, S; Bon, GB; Campbell, LM; Egros, F; Farnier, M; Fayyad, R; Langan, J; Mahla, G; Nawrocki, JW; Pauciullo, P; Sirtori, C | 1 |
| Roberts, WC | 1 |
| Baetta, R; Calore, M; Comparato, C; Donetti, E; Fumagalli, R; Paoletti, R; Rossi, A; Soma, MR; Teruzzi, C | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| Lane, M; Laskarzewski, P; Stein, EA | 1 |
| Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Pincus, J | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Blanco-Colio, LM; Egido, J; Guijarro, C; Kasiske, BL; Keane, WF; Massy, ZA; O'Donnell, MP | 1 |
| Frohlich, BH; Gregg, RE; Tesfamariam, B | 1 |
| Kivistö, KT; Lilja, JJ; Neuvonen, PJ | 1 |
| Branchi, A; Fiorenza, AM; Macor, S; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 1 |
| Farnier, M | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Hecker, M; Just, I; Köhler, T; Rückschloss, U; Wagner, AH | 1 |
| Bakker-Arkema, RG; Black, DM; Nawrocki, JW | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Blair, SN; Capuzzi, DM; Cater, NB; Gottlieb, SO; Morgan, JM; Nguyen, T | 1 |
| Branzi, A; Carinci, V; Magelli, C; Magnani, G; Potena, L; Reggiani, LB | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| Huang, J; Kiener, PA; Knapp, AC; Starling, G | 1 |
| Brown, WV | 1 |
| Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| Kwak, B; Mach, F; Mulhaupt, F; Myit, S | 1 |
| Davidson, MH | 1 |
| Stein, EA | 2 |
| Crouch, MA | 1 |
| Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M | 1 |
| Jackson, G | 2 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; O'Malley, PG; Taylor, AJ | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D | 1 |
| Hilleman, DE; Lenz, TL; Wurdeman, RL | 1 |
| Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK | 1 |
| Beinlich, CJ; Ichihara, K; Morgan, HE; Satoh, K; Shirota, F; Tsunajima, T | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Maclaine, GD; Patel, H | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Anthony, M; Bleske, BE; Casselberry, N; Datwani, M; Secontine, SG; Shea, MJ; Uhley, VE; Willis, RA | 1 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH | 1 |
| Auer, J; Eber, B | 1 |
| Conradie, MM; Gopal, R; Hough, S; Hulley, PA; Maritz, FJ | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Ichihara, K; Kaneta, S; Marumo, H; Satoh, K; Yamamoto, A | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bazalo, GR | 1 |
| Alfón, J; Badimon, L; Berrozpe, M; Martínez-González, J | 1 |
| Hsue, PY; Waters, DD | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Jialal, I; Stein, DT | 1 |
| Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F | 1 |
| Berthier, S; Hartmann, S; Hubert, M; Kovarik, JM; Rordorf, C; Rosenkranz, B; Schneider, W | 1 |
| Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN | 1 |
| Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y | 1 |
| Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH | 1 |
| Athyros, VG; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Piliero, PJ | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L | 1 |
| Hinman, J; Scanu, AM | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Shah, PK | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ; Vernalis, MN | 1 |
| SoRelle, R | 1 |
| Chmielewski, M; Rutkowski, B; Zdrojewski, Z | 1 |
| Blaschke, F; Bokemeyer, J; Fleck, E; Goetze, S; Graf, K; Kappert, K; Kintscher, U; Schmidt, G; Stawowy, P | 1 |
| Frolkis, JP; Minor, S; Nambi, V; Pearce, GL; Sprecher, DL | 1 |
| Bates, ER; Carville, DG; Guyer, KE; Hopp, AS; Horowitz, K; Lau, WC; Neer, CJ; Tait, AR; Waskell, LA; Watkins, PB | 1 |
| Sinzinger, H | 1 |
| Angori, P; Auteri, A; Bova, G; Bruni, F; Cercignani, M; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Derhaschnig, U; Dorner, GT; Jilma, B; Joukhadar, C; Petternel, V; Rassoul, F; Richter, V; Wagner, OF; Wolzt, M | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ | 2 |
| Krane, V; Wanner, C | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 2 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Fuller, S; Gillen, D; Lacey, L; Marriott, J; Wilson, K | 1 |
| McBurney, CR; Smith, DG | 1 |
| Clark, LT | 1 |
| Liebson, PR | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Sudhop, T; von Bergmann, K | 1 |
| Betz, W; Devroey, D; Duquet, W; Velkeniers, B | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Slavina, NN; Vaulin, NA | 1 |
| Berkenboom, G; Fontaine, D; Fontaine, J; Otto, A | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Nasu, M; Tamura, A; Watanabe, T | 1 |
| Kent, SM; Taylor, AJ | 1 |
| Brown, WV; Moussa, M | 1 |
| Ichihara, K; Kanda, M; Satoh, K | 1 |
| Gupta, S | 1 |
| Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A | 1 |
| Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM | 1 |
| Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K | 1 |
| Ruef, J | 1 |
| März, W | 3 |
| Kröger, K; Wittlinger, T | 1 |
| Edwards, JE; Moore, RA | 1 |
| Einecke, D | 4 |
| Cannon, CP | 1 |
| Mach, F | 1 |
| Brodie, B; Brown, BG; Cooper, CJ; Crowe, T; DeMaria, AN; Ganz, P; Grines, CL; Howard, G; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Vogel, RA | 1 |
| Sacks, FM | 1 |
| Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM | 1 |
| Topol, EJ | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD | 1 |
| Fukazawa, I; Uchida, E; Uchida, N; Yasuhara, H | 1 |
| Fang, CH; Li, JJ | 1 |
| Tellier, P | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Kulbertus, H; Scheen, AJ | 1 |
| Hobbs, RA; Tafreshi, MJ | 1 |
| Fujisaki, K; Itoh, Y; Kubota, T; Oishi, R; Sendo, T; Yano, T | 1 |
| Salam, AM | 1 |
| Nissen, S | 1 |
| Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM | 1 |
| van der Harst, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Hegmann, T | 1 |
| LeLorier, J; Paradis, JM | 1 |
| Gotto, AM | 2 |
| Miller, M | 1 |
| Auer, J; Eber, B; Weber, T | 1 |
| Egido, J; Tuñón, J | 1 |
| Jacobson, TA | 1 |
| Cannon, CP; Ray, KK | 2 |
| Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Deedwania, PC | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM | 1 |
| Endo, K; Ito, Y; Koide, N; Miyashita, Y; Otsuka, M; Oyama, T; Ozaki, H; Saiki, A; Shirai, K | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Isley, WL | 1 |
| Fitchett, DH; Goodman, S; Langer, A; Leiter, LA; Tardif, JC | 1 |
| Ilkay Alp, F; Kaleli, D; Ozdemir, O; Sönmez Uydeş-Doğan, B; Takir, S; Topal, G | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Cheng, TO | 1 |
| Farmer, JA | 2 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Arimochi, H; Hagiwara, M; Kataoka, K; Kuwahara, T; Nakayama, H; Ohnishi, Y | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Alsheikh-Ali, AA; Karas, RH | 2 |
| Curtiss, FR | 1 |
| Bittolo Bon, G; Calabresi, L; Cattin, L; Fellin, R; Manzato, E; Montagnani, M; Pauciullo, P; Pisciotta, L; Sirtori, CR | 1 |
| Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Berna, C; Calmy, A; Junod, AF; Peytremann-Bridevaux, I | 1 |
| Jones, P; Miller, PS; Smith, DG | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Nishikata, M; Yasuda, N | 1 |
| Cannon, CP; Reid, IR; Tonkin, A | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Fujita, H; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Murata, I; Okubo, M; Sano, K; Tsuchiya, K; Yokoyama, H; Zhou, X | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Auer, J; Eber, B; Lamm, G | 1 |
| Hirose, T; Kawamori, R; Ohmura, C; Tanaka, Y; Watada, H | 1 |
| Miyashita, Y; Murano, T; Oyama, T; Saiki, A; Shirai, K; Watanabe, F | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Gustafsson, I; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Stender, S; Torp-Pedersen, C | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H; Straussberg, R | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K | 1 |
| Cicero, AF; Gaddi, A | 1 |
| Boehlen, F; Daali, Y; de Moerloose, P; Fontana, P; Mach, F; Reber, G; Senouf, D; Sigwart, U | 1 |
| Damkier, P; Hallas, J; Korsholm, L; Kristensen, SR; Mickley, H; Poulsen, TS; Vinholt, P | 1 |
| Austin, PC; Mamdani, MM | 1 |
| Nissen, SE | 2 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Field, KM | 1 |
| Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O | 1 |
| Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Jackson, G; McCabe, CH; Ray, KK; Sacks, FM; Tonkin, AM | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Ridker, PM; Rifai, N; Skene, AM | 1 |
| Davidson, M | 1 |
| Amarenco, P; Labreuche, J; Lavallée, PC; Touboul, PJ | 1 |
| Amyot, R; Arnold, M; Bonafede, N; Cannon, CP; Dupuis, J; Lonn, E; Ricci, J; Rouleau, JL; Roux, R; Tardif, JC; Title, LM; Woo, A | 1 |
| Phillips, PS | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H | 3 |
| Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Fonarow, GC | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Rouleau, J | 1 |
| Crowe, T; Kapadia, S; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M | 1 |
| Graselli, U; Joukhadar, C; Kostner, K; Lackner, E; Thallinger, C; Urbauer, E; Wolzt, M | 1 |
| Aldama-López, G; Campo-Pérez, R; Castro-Beiras, A; Crespo-Leiro, MG; Llinares-García, D; Marzoa-Rivas, R; Muñiz-Garcia, J; Paniagua-Marin, MJ; Piñón-Esteban, P | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Chen, MS; Crowe, T; Kapadia, S; Loyd, AB; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Crespo, MJ; Quidgley, JA | 1 |
| Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T | 1 |
| Pilote, L; Rahme, E; Zhou, Z | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Koter-Michalak, M | 1 |
| Clearfield, M | 1 |
| Fukazawa, M; Ishikawa, M; Kubota, T; Moroi, M; Namiki, A; Sugi, K; Yajima, S | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Rosenson, RS | 1 |
| Dincer, I; Erol, C; Ertas, F; Ongun, A; Ozdol, C; Turhan, S | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Maurer, G; Pammer, J; Pfaffenberger, S; Rega, G; Wojta, J | 1 |
| Brown, BG | 1 |
| Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Gehr, BT; Porzsolt, F; Weiss, C | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T | 1 |
| Hayashi, T; Ka, Y; Kitamura, A; Matsumura, Y; Mori, T; Ohkita, M; Sugii, M; Takaoka, M | 1 |
| Braunwald, E; Cannon, CP; Jarolim, P; McCabe, CH; Morrow, DA; Ray, KK; Sabatine, MS; Scirica, BM; Shui, A | 1 |
| Dörge, H; Grabedünkel, J; Liakopoulos, OJ; Nagorsnik, U; Schmitto, JD; Schoendube, FA | 1 |
| Apperson-Hansen, C; Churchill, T; Crowe, T; Lin, S; Loyd, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wang, C; Wolski, K | 1 |
| Plans-Rubió, P | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM | 1 |
| Buerke, M; Hennen, R; Keller, A; Müller-Werdan, U; Russ, M; Schmidt, H; Werdan, K | 1 |
| Allemann, C; Babiychuk, EB; Draeger, A; Hoppeler, H; Mohaupt, M; Monastyrskaya, K; Savolainen, H | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Iwashita, M; Kono, S; Sasaki, J | 1 |
| Braunwald, E; Giugliano, RP | 1 |
| Akers, WS; Steinhubl, SR | 1 |
| Poli, A; Pujia, A | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Carod-Artal, FJ | 1 |
| Knopp, RH; Paramsothy, P | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G | 1 |
| Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 1 |
| Barron, TI; Bennett, K; Feely, J | 1 |
| Mistafa, O; Roudier, E; Stenius, U | 1 |
| Cannon, CP; Ganz, P; Ray, KK | 1 |
| Mason, RP | 1 |
| Moriguchi, H; Sato, C; Uemura, T | 1 |
| Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L | 1 |
| Inoue, N; Ishikawa, M; Kato, T; Motomura, K; Oikawa, S; Okajima, F; Shimano, H; Takahashi, A; Yamada, N | 1 |
| Billinger, M; Cook, S; Haeberli, A; Hess, OM; Meier, B; Togni, M; Wenaweser, P; Windecker, S | 1 |
| Bairey Merz, CN; Cosin-Aguilar, J; Deedwania, P; Koylan, N; Luo, D; Ouyang, P; Piotrowicz, R; Schenck-Gustafsson, K; Sellier, P; Stein, JH; Stone, PH; Thompson, PL; Tzivoni, D | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Abe, M; Hirose, T; Kawamori, R; Mita, T; Nakayama, S; Ogihara, T; Shimizu, T; Uchino, H; Watada, H | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Koter-Michalak, M | 1 |
| Batt, AM; Bertrand-Thiebault, C; Masson, C; Siest, G; Visvikis-Siest, S | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A | 1 |
| Frial, T; Miller, PS; Tran, YB | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
| Chen, C; Lin, J; Smolarek, T; Tremaine, L | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Tomiyama, N; Yasuda, N | 1 |
| Bhatt, DL; Brennan, DM; Fox, K; Mak, KH; Saw, J; Steinhubl, SR; Topol, EJ | 1 |
| Coleman, CI; Dale, KM; Henyan, NN; Kluger, J; White, CM | 1 |
| George, J; Keren, G; Luboshits, G; Mausner-Fainberg, K; Maysel-Auslender, S; Mor, A; Rubinstein, A | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Averna, MR; Bucciarelli, L; Cefalù, AB; Ciabattoni, G; Davì, G; Davì, V; Ferrante, E; Noto, D; Pettinella, C; Santilli, F | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Cannon, CP; Kumar, A | 1 |
| Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA | 1 |
| Eggen, AE; Engeland, A; Furu, K; Hartz, I; Njølstad, I; Sakshaug, S; Skurtveit, S | 1 |
| Han, YL; Kang, J; Li, CY; Li, Y; Yan, CH | 1 |
| Braunwald, E; Buros, J; Cannon, CP; Croce, K; Gao, H; Healy, AM; Libby, P; McCabe, CH; Morrow, DA; Pradhan, AD; Sabatine, MS; Sakuma, M; Simon, DI; Wang, Y | 1 |
| Dal Pan, G; McAdams, M; Staffa, J | 1 |
| Shaley, FM | 1 |
| Blazing, M; Cannon, CP; Gersh, B; McLean, DS; Ravid, S; Shui, A | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Braunwald, E; Cannon, CP; Catanese, JJ; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Ranade, K; Rowland, CM; Sabatine, MS; Simonsen, KL; Tong, CH | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK | 1 |
| Asberg, A; Gedde-Dahl, A; Hejazifar, S; Hoel, K; Skottheim, IB | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Abe, Y; Furukado, S; Hori, M; Hoshi, T; Hougaku, H; Kitagawa, K; Sakaguchi, M; Yamagami, H | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Avisar, I; Brook, JG; Wolfovitz, E | 1 |
| Farmer, JA; Jones, PH | 1 |
| Ando, H; Fujimura, A; Kaneko, S; Saito, T; Sugimoto, K; Takamura, T; Tsuruoka, S; Yanagihara, H | 1 |
| Burke, A; FitzGerald, GA; Ky, B; Rader, DJ; Szapary, PO; Tadesse, MG; Tsimikas, S; Witztum, JL; Wolfe, ML | 1 |
| Gratsianskii, NA; Vaulin, NA | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Ichihara, K; Itagaki, M; Satoh, K; Takaguri, A; Tokumitsu, Y | 1 |
| Doggrell, SA | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Fildes, JE; Leonard, CT; Mitsidou, A; Rogacev, K; Shaw, SM; Williams, SG; Yonan, N | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| Xiao, H; Yang, CS | 1 |
| Chae, A; Choi, SH; DeMaria, AN; Messig, M; Miller, E; Nissen, SE; Ntanios, F; Tsimikas, S; Witztum, JL | 1 |
| Nambi, V; Polsani, VR; Virani, SS | 1 |
| Ford, JS; Tayek, JA | 1 |
| Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Braunwald, E; Cannon, CP; Giraldez, RR; Giugliano, RP; McCabe, CH; Mohanavelu, S; Murphy, SA | 1 |
| Gamie, Z; Graham, S; Linder, T; Tang, QO; Tran, GT; Tsialogiannis, E; Tsiridis, E | 1 |
| Burke, JP; Dhonnchu, TN; Maher, BM; Soo, A; Watson, RW; Wood, AE | 1 |
| Mullangi, R; Srinivas, NR | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D | 1 |
| Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA | 1 |
| Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P | 1 |
| Fukumoto, Y; Rashid, M; Seto, M; Shimokawa, H; Tawara, S; Yano, K | 1 |
| Itoh, T; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Shen, J; Zhang, Q; Zhang, RY | 1 |
| Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Morrow, DA; Ray, KK; Ridker, PM | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Abel, T; Fehér, J | 1 |
| Lüscher, TF | 1 |
| Satoh, A; Satoh, M | 1 |
| Kapoor, AS; Majumdar, SR; McAlister, FA; Mohamed, R; Norris, CM; Pretorius, V; Ross, DB | 1 |
| Alonso, J; Cardier, JE; Ledezma, E; Wittig, O | 1 |
| Cannon, CP; Gibson, CM; McCabe, CH; Murphy, SA; Tung, P; Wiviott, SD | 1 |
| Itoh, T; Maesawa, C; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Kashima, Y; Koshikawa, M; Koyama, J; Kumazaki, S; Tomita, T; Tsutsui, H | 1 |
| Brown, A; Cannon, CP; Mega, JL; Morrow, DA; Sabatine, MS | 1 |
| Boari, B; Manfredini, F; Manfredini, R; Salmi, R | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D | 1 |
| Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP | 1 |
| Cannon, CP; Gibson, CM; Hochberg, CP; Pride, YB; Sabatine, MS; Sloan, S | 1 |
| Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J | 1 |
| Arishiro, K; Hanafusa, T; Hoshiga, M; Ishihara, T; Kohbayashi, E; Miyazaki, N; Nakakoji, T; Negoro, N; Okabe, T | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Han, YL; Jing, QM; Li, Y; Wang, DM; Wang, SL; Wang, ZL; Zhang, ZL | 1 |
| Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J | 1 |
| King, S; Superko, HR | 1 |
| de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A | 1 |
| King, S; Momary, K; Superko, HR | 1 |
| Barber, MJ; Chasman, DI; Chatterjee, A; Hyde, CL; Krauss, RM; Li, X; Mangravite, LM; McCarty, CA; Nickerson, DA; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Wilke, RA; Williams, PT | 1 |
| Arai, H; Ito, F; Miyagi, N; Someya, T; Tamura, K; Ushiyama, T | 1 |
| Cairns, R; Cannon, CP; Michael Gibson, C; Nazer, B; Ray, KK | 1 |
| Watson, KE | 1 |
| Strandberg, TE | 1 |
| Berk, M; Henry, MJ; Jacka, FN; Kotowicz, MA; Nicholson, GC; Pasco, JA; Williams, LJ | 1 |
| Cannon, CP; Khera, AV; Qin, J; Rader, DJ; Wolfe, ML | 1 |
| Akishita, M; Eto, M; Iijima, K; Kahyo, T; Kano, MR; Ogawa, S; Ota, H; Ouchi, Y; Setou, M | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Atanasova, P; Bełtowski, J; Chaldakov, GN; Chylińska-Kula, B; Jamroz-Wiśniewska, A; Wójcicka, G | 1 |
| Bangalore, S; Cannon, CP; Murphy, SA; Qin, J; Sloan, S | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Cheng, KA; Cheng, Z; Ding, L; Fang, F; Fang, Q; Liu, Y; Shi, GP | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Doi, M; Fukushima, H; Hamada, M; Matsui, H; Mizuno, T; Nishio, K; Shida, Y; Shima, M; Sugimoto, M; Yoshioka, A | 1 |
| Wilke, RA | 1 |
| Betteridge, J | 1 |
| Ashour, S; Bahbouh, M; Khateeb, M | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Nazer, B; Ray, KK; Scirica, B; Sloan, S | 1 |
| Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T | 1 |
| Asuphol, O; Chaiyakunapruk, N; Dhippayom, T; Jeanpeerapong, N; Poowaruttanawiwit, P | 1 |
| Caretta, G; Dei Cas, L; Della Pina, P; Gorga, E; Madureri, A; Raddino, R | 1 |
| Belo, VA; Gerlach, RF; Guimaraes, DA; Izidoro-Toledo, TC; Tanus-Santos, JE | 1 |
| Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Abela, GS; Durga, S; Huang, R; Janoudi, A; Tamhane, U; Vedre, A | 1 |
| Shi, J; Xue, Z | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Azuma, Y; Fujita, T; Haruyama, Y; Ikeda, Y; Kumagai, Y; Maeda, K; Sugiyama, Y; Yamane, N; Yoshida, K | 1 |
| Atanassova, P; Bełtowski, J; Chaldakov, GN; Jamroz-Wiśniewska, A; Kula, W; Rusek, M | 1 |
| Ali, OF; Butrous, GS; Growcott, EJ; Wharton, J | 1 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Fullerton, DA; Meng, X; Reece, TB; Reppert, AE; Sadaria, MR; Weyant, MJ; Yu, JA | 1 |
| Braunwald, E; Cannon, CP; Grandin, EW; Jarolim, P; Morrow, DA; Murphy, SA; Ritterova, L | 1 |
| Komatsu, T; Kunugita, F; Nakamura, M; Ozawa, M; Sato, Y; Tachibana, H | 1 |
| Luzak, B; Rywaniak, J; Stanczyk, L; Watala, C | 1 |
| Choudhury, RP; Iacob, AO | 1 |
| Bonaca, MP; Bui, AH; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Itoh, H; Mitsuishi, M; Miyashita, K; Muraki, A; Tamaki, M; Tanaka, K | 1 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Jin, J; Kim, BY; Kim, DE; Kim, EK; Kim, JS; Lee, DK; Lee, H; Park, EJ; Shin, IJ | 1 |
| Aukrust, P; Breland, UM; Hagelsteen, K; Halvorsen, B; Haraldsen, G; Hol, J; Kasprzycka, M; Otterdal, K; Pedersen, TM; Ranheim, T; Stang, E | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Erkoseoglu, I; Kadioglu, M; Kalyoncu, NI; Kesim, M; Muci, E; Okuyan, M; Yaris, E | 1 |
| Li, L; Nouraldeen, A; Wilson, AG | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Clark, K; Galloway, S; Lam, V; Mamo, J; Pallebage-Gamarallage, M; Takechi, R | 1 |
| Bang, CN; Gislason, GH; Greve, AM; Køber, L; Torp-Pedersen, C; Wachtell, K | 1 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK | 1 |
| Rosenberg, JL | 1 |
| Huang, CF; Lo, WT; Peng, HJ; Shih, YL; Wu, CC; Wu, TC | 1 |
| Biro, S; Ikeda, Y; Kono, S; Otonari, T; Sasaki, J; Uchida, Y | 1 |
| Latorre, A; Madrid, I; Moscardó, A; Santos, MT; Vallés, J | 1 |
| Alawi, M; Arafat, T; Awwad, AA; Yacoub, M | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Lee, CW; Park, SJ | 1 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Butterton, JR; Feng, HP; Gupta, S; Hulskotte, EG; O'Mara, E; van Zutven, MG; Wagner, JA; Xuan, F | 1 |
| Bare, LA; Devlin, JJ; Iakoubova, OA; Leahy, KJ; O'Sullivan, AK; Parthan, A; Weinstein, MC | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Gitirana, LB; Machado, MN; Magalhães, CB; Melo, AC; Porto, LC; Ribeiro, ML; Santos, JC; Valença, SS; Zin, WA | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Marrion, NV; Robertson, JD; Robinson, ES; Stuart, SA | 1 |
| Catapano, AL; Corrao, G; Ibrahim, B; Mancia, G; Merlino, L; Nicotra, F; Pasini, TS; Zambon, A | 1 |
| Bao, JQ; Fallon, JK; Higgins, JW; Ke, AB; Manro, JR; Smith, PC; Zamek-Gliszczynski, MJ | 1 |
| Aukrust, P; Holven, KB; Nenseter, MS; Ose, L | 1 |
| Duleba, AJ; Ortega, I; Sokalska, A; Stanley, SD; Villanueva, JA | 1 |
| Al-Hamaq, AO; Barakat, L; Bener, A; Dogan, M | 1 |
| Casiano, H; Crespo, MJ; Cruz, N; Hernandez, C; Quidgley, J; Rivera, K; Torres, H | 1 |
| Barroso, MV; Benjamim, CF; de Brito-Gitirana, L; Ferreira, TS; Lanzetti, M; Porto, LC; Rueff-Barroso, CR; Valença, SS | 1 |
| Cannon, CP; de Lemos, J; Guo, J; Lewis, EF; Mega, JL; O'Donoghue, ML; Rouleau, JL; Sabatine, MS; Sarma, A | 1 |
| Bátai-Konczos, A; Jemnitz, K; Kékesi, O; Kis, E; Szabó, K; Szabó, M; Veres, Z | 1 |
| Cao, YJ; Du, HP; Hu, LF; Li, J; Liu, CF; Liu, H; Wang, F; Wang, YL; Xu, R; Xu, Y; You, SJ | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H | 1 |
| Dohi, T | 1 |
| Arora, RC; Bellan, D; Freed, DH; Kirshenbaum, LA; Li, Y; Müller, AL; Ngo, MA; Sran, K | 1 |
| Bansal, A; Burkholder, G; Goepfert, PA; Kahan, SM; Overton, ET; Sterrett, S; Westfall, AO; Zajac, AJ | 1 |
| Assassi, AL; Auzerie, J; Gaudin, K; Hamon, T; Perovitch, P; Roy, CE | 1 |
| Joos, TO; Marcus, K; Nuessler, AK; Planatscher, H; Poetz, O; Reuss, M; Schnabel, A; Serschnitzki, B; Stoll, D; Templin, MF; Thasler, WE; van den Berg, BH; Weiß, F; Weiss, TS | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Cogo-Müller, K; Cuzzullin, MC; de Andrade, ED; Franco, GC; Graziano, TS; Groppo, FC; Schwartz-Filho, HO | 1 |
| Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS | 1 |
| Gandhi, HP; Patel, SS; Rathod, SP; Trivedi, JI; Variya, BC | 1 |
| Al-Badriyeh, D; Al-Khal, A; Alabbadi, I; Fahey, M; Zaidan, M | 1 |
| Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, JH; Kim, JS; Ko, YG; Shin, DH | 1 |
| Hua, L; Li, Y; Liu, H; Wang, D; Xiong, X; Zhao, H | 1 |
| Gouya, G; Herkner, H; Mesgarpour, B; Reichardt, B; Wolzt, M | 1 |
| Anzalone, DA; Cain, VA; Friday, KE; Lewis, SJ; Welty, FK | 1 |
| Kudo, S; Minami, T; Miyata, S; Nogi, M; Satoh, K; Shimokawa, H; Tanaka, S | 1 |
| Deedwania, PC; Fayyad, RS; Laskey, RE; Stone, PH; Wilson, DJ | 1 |
| Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF | 1 |
| Zhao, SP; Zhao, W | 1 |
| Banefelt, J; Fox, KM; Gandra, SR; Hallberg, S; Johansson, G; Levin, LÅ; Mesterton, J; Sobocki, P | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Srinivas, NR | 1 |
| Hong, JM; Lee, JS; Lim, SG; Park, RW; Shin, D; Yoon, D | 1 |
| Cooper, LS; Dunning, A; Fiuzat, M; Fleg, JL; Kelly, JP; Keteyian, SJ; Kitzman, DW; Kraus, WE; Leifer, ES; Mentz, RJ; O'Connor, CM; Pina, IL; Schulte, PJ; Whellan, DJ | 1 |
| Bonaca, MP; Braunwald, E; Cannon, CP; Conrad, MJ; Jarolim, P; Morrow, DA; Murphy, SA; O'Malley, RG; Sabatine, MS; Scirica, BM; White, HD | 1 |
| Corkum, A; Fisher, J; Minard, LV; Saleh, A; Sketris, I; Zhang, Y | 1 |
| Banach, M; Blaha, MJ; Chruściel, P; Jones, SR; Lip, GY; Martin, SS; Mikhailidis, DP; Mosteoru, S; Pencina, MJ; Ray, KK; Rembek-Wieliczko, M; Rysz, J; Sahebkar, A; Serban, MC; Toth, PP; Ursoniu, S | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Chen, YC; Chen, YH; Hsieh, MC; Liu, CS | 1 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Colas, RA; Dalli, J; Souza, PR; Walker, ME | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| Corradi, JP; Dicks, R; Duan, Y; Grady, J; Mather, JF; Noyes, A; Waszynski, C | 1 |
| Murphy, G; Murphy, JEJ; O'Gorman, SM; Powers, JM; Ralph, N | 1 |
| Barton, HA; Li, R | 1 |
| Ahn, CM; Cheong, SS; Cho, DK; Cho, YH; Choi, D; Her, AY; Hong, MK; Im, E; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Lee, K; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Lopez, D; Melendez, QM; Wooten, CJ | 1 |
| Averna, M; Bugliani, M; Di Mauro, S; Di Pino, A; Filippello, A; Marchetti, P; Noto, D; Piro, S; Purrello, F; Rabuazzo, AM; Scamporrino, A; Scicali, R; Urbano, F | 1 |
| Broniarek, I; Jarmuszkiewicz, W | 1 |
| Cannon, CP; Guo, J; Khan, N; Steen, DL; Umez-Eronini, AA | 1 |
| Apola, A; Kwiecień, A; Maślanka, A; Opoka, W; Stolarczyk, M | 1 |
| Butts, M; Spiro, J | 1 |
| Chen, X; Li, Y; Lin, L; Wang, S; Zhang, H | 1 |
| Cook, RL; Dave, CV; Hartzema, AG; Park, H; Winterstein, AG | 1 |
| Alvarez, EA; Busija, AR; Dalton, ND; Drummond, JC; Godoy, JC; Kararigas, G; Kassan, A; Niesman, IR; Patel, HH; Roth, DM; Schilling, JM; Schwarz, A; Zemljic-Harpf, AE | 1 |
| Liu, G; Liu, M; Wang, M | 1 |
| Aschmann, HE; Puhan, MA; Yebyo, HG | 1 |
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Duleba, AJ; Hawkins, AB; Sokalska, A; Yamaguchi, T | 1 |
| Benet, LZ; Bowman, CM; Okochi, H | 1 |
| Albertsson, M; Holmqvist, A; Kotti, A; Sun, XF | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Au, A; Basu, S; Collier, VJ; Hopkin, G; Naci, H; Yudkin, JS | 1 |
| Gordts, PLSM; Nora, C; Tsimikas, S; Witztum, JL; Yeang, C | 1 |
| Dobs, AS; Duprez, DA; Folsom, AR; Konety, SH; Kronmal, RA; Oluleye, OW; Ouyang, P; Vaidya, DM; Yarmohammadi, H | 1 |
| Chen, Z; Gadiyaram, V; Lopaschuk, G; Raggi, P; Stillman, AE; Zhang, C | 1 |
| Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Marzolini, C; Spaggiari, D | 1 |
| Caspar, AT; Hemmer, S; Meyer, MR; Wagmann, L | 1 |
| de Fijter, JW; Dekker, FW; Dekkers, OM; Esmeijer, K; Hoogeveen, EK | 1 |
| Broniarek, I; Dominiak, K; Galganski, L; Jarmuszkiewicz, W | 1 |
| Attalah Nee Rezkallah, C; Chen, QM; Thongkum, A; Zhu, C | 1 |
| Hoang, T; Kim, J | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Dymkowska, D; Wrzosek, A; Zabłocki, K | 1 |
| Butterton, JR; Caro, L; Fandozzi, CM; Feng, HP; Fraser, IP; Guo, Z; Iwamoto, M; Levine, V; Panebianco, D; Prueksaritanont, T; Swearingen, D; Wolford, D; Yeh, WW | 1 |
| Aksoy, HN; Ceylan, C | 1 |
| Abrahamsson, B; Agrawal, R; Bergenholm, L; Björkbom, A; Bright, J; Cavallin, A; Gopaul, VS; Hammarberg, M; Hawthorne, G; Hurt-Camejo, E; Jansson-Löfmark, R; Jarke, A; Johansson, MJ; Li, X; Lundborg, E; Pieterman, EJ; Princen, HMG; Svensson, L | 1 |
| Abraldes, JG; Al-Karaghouli, M; Cabrera Garcia, L; Kalainy, S; Sung, S | 1 |
| Barwiolek, M; Budny, M; Ciarkowska, A; Kozakiewicz, A; Loch, JI; Sokolowska, Z; Wojtczak, A; Wujak, M | 1 |
| Alani, M; Anderson, K; Gong, Q; Nelson, CH; Othman, AA; Tarnowski, T | 1 |
| Corbella, E; Corbella, X; Díaz-Díaz, JL; Martínez-Porqueras, R; Pintó, X; Rodríguez-Sánchez, MA; Ruíz-García, A; Sánchez-Ruíz-Granado, E; Sarasa, I; Suárez-Tembra, M; Trias, F | 1 |
| Aschenbrenner, DS | 1 |
| Chowdhury, EK; Curtis, AJ; Ernst, ME; McNeil, JJ; Murray, AM; Nelson, MR; Reid, CM; Ryan, J; Tonkin, AM; Wolfe, R; Woods, RL; Zhou, Z; Zoungas, S | 1 |
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
| Ballotari, M; Bortolotti, F; Gottardo, R; Tagliaro, F; Taus, F | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
| Furugen, A; Kobayashi, M; Mukai, Y; Narumi, K; Sakuma, T; Yamaguchi, A | 1 |
| Filppula, AM; Hirvensalo, P; Keskitalo, J; Kiiski, JI; Lönnberg, KI; Mustaniemi, AL; Niemi, M; Tornio, A | 1 |
| Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF | 1 |
| Adams, SP; Alaeiilkhchi, N; Tasnim, S; Wright, JM | 1 |
85 review(s) available for atorvastatin and pravastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparison of statins in hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome | 2000 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Benefits and menaces related to the use of statins in patients after renal transplantation.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin | 2002 |
Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Renal Dialysis; Simvastatin | 2003 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2004 |
[Interactions of statins with antithrombotic drugs].
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Pyrroles; Rats; Ticlopidine; Time Factors | 2004 |
[LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Placebos; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2003 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
The next step in cardiovascular protection.
Topics: Angina, Unstable; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Maximum Tolerated Dose; Practice Guidelines as Topic; Pravastatin; Prognosis; Pyrroles; Quebec; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome | 2005 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Stroke prevention, blood cholesterol and statins.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Factors; Stroke | 2005 |
In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Ischemia; Pravastatin; Pyrroles; Syndrome; Treatment Outcome | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutic Equivalency; Treatment Outcome | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
The fading of reported effectiveness. A meta-analysis of randomised controlled trials.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Heptanoic Acids; Humans; Intraocular Pressure; Latanoprost; Pravastatin; Prostaglandins F, Synthetic; Publication Bias; Pyrroles; Randomized Controlled Trials as Topic; Sample Size; Selection Bias; Time Factors; Timolol; Treatment Outcome | 2006 |
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Topics: Acute Disease; Atorvastatin; Cardiac Output, Low; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Natriuretic Peptide, Brain; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome | 2006 |
Statins: beneficial or adverse for glucose metabolism.
Topics: Atorvastatin; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles | 2006 |
The year in non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Prognosis; Pyrroles; Risk Assessment; Stents; Syndrome; Thrombolytic Therapy; Ticlopidine | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2006 |
Molecular basis of differences among statins and a comparison with antioxidant vitamins.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrroles; Vitamins | 2006 |
Impact of statin dosing intensity on transaminase and creatine kinase.
Topics: Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Transaminases | 2007 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Statins: under investigation for increasing bone mineral density and augmenting fracture healing.
Topics: Animals; Atorvastatin; Bone Density; Bone Morphogenetic Protein 2; Clinical Trials as Topic; Fracture Healing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 9; Osteoclasts; Pravastatin; Pyrroles; Simvastatin; Vascular Endothelial Growth Factor A | 2008 |
Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies.
Topics: Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Indoles; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine | 2009 |
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk | 2008 |
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention | 2010 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult | 2016 |
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Regression Analysis; Rosuvastatin Calcium; Simvastatin | 2016 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Statin therapy increases lipoprotein(a) levels.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium | 2020 |
Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.
Topics: Atorvastatin; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lovastatin; Network Meta-Analysis; Pravastatin; Proteinuria; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2019 |
Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2020 |
A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Pravastatin; Simvastatin | 2021 |
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; Humans; Ischemic Stroke; Metoprolol; Pravastatin; Probucol; Rosuvastatin Calcium; Stroke; Warfarin | 2023 |
Pravastatin for lowering lipids.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug-Related Side Effects and Adverse Reactions; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Pravastatin; Rosuvastatin Calcium | 2023 |
157 trial(s) available for atorvastatin and pravastatin
| Article | Year |
|---|---|
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Beverages; Citrus; Cross-Over Studies; Female; Gas Chromatography-Mass Spectrometry; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Volunteers | 1999 |
Lowering effects of four different statins on serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1999 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Margarine; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Sitosterols; Treatment Outcome; Triglycerides | 2000 |
Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Topics: Adult; Anticholesteremic Agents; Antifungal Agents; Area Under Curve; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Pravastatin; Pyridines; Pyrroles; Reference Values; Time Factors | 2000 |
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome | 2001 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness.
Topics: Atorvastatin; Carotid Artery, Common; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Tunica Intima; Tunica Media | 2001 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed | 2001 |
The effect of pravastatin and atorvastatin on coenzyme Q10.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Coenzymes; Coronary Disease; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Triglycerides; Ubiquinone | 2001 |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States | 2001 |
Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2001 |
Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Topics: Adult; Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Everolimus; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Mass Spectrometry; Middle Aged; Pravastatin; Pyrroles; Sirolimus | 2002 |
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; HIV Seronegativity; Human Experimentation; Humans; Pravastatin; Pyrroles; Ritonavir; Saquinavir; Simvastatin | 2002 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome | 2001 |
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2002 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Topics: Adult; Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2002 |
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.
Topics: Adolescent; Adult; Atorvastatin; Breath Tests; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine | 2003 |
Time-dependent effect of statins on platelet function in hypercholesterolaemia.
Topics: Adult; Analysis of Variance; Antiporters; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol; Cross-Sectional Studies; Double-Blind Method; E-Selectin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Effect of atorvastatin and pravastatin on serum C-reactive protein.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2003 |
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors | 2003 |
[Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Electrocardiography; Female; Heptanoic Acids; Homeostasis; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Syndrome; Time Factors | 2003 |
Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles | 2003 |
Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection.
Topics: Aged; Atorvastatin; C-Reactive Protein; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Pravastatin; Pyrroles; Tunica Intima; Tunica Media | 2003 |
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2003 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2004 |
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Observer Variation; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles | 2004 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2004 |
Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Beverages; Citrus; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Pravastatin; Pyrroles | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil | 2004 |
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention | 2005 |
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional | 2005 |
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein Lipase; Middle Aged; Pravastatin; Pyrroles | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Particle Size; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides | 2005 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome | 2005 |
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Topics: Adolescent; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound.
Topics: Aged; Atorvastatin; Coronary Stenosis; Drug Administration Schedule; Echocardiography, Three-Dimensional; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Reproducibility of Results; Ultrasonography, Interventional | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors | 2005 |
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; Time Factors | 2005 |
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors; Syndrome | 2005 |
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial).
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Syndrome; Ultrasonography; Vasodilation | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T | 2006 |
The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2006 |
[Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Statistics, Nonparametric; Triglycerides | 2005 |
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2006 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Topics: Adaptation, Physiological; Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Prospective Studies; Pyrroles; Risk Factors; Single-Blind Method; Triglycerides; Ultrasonography, Interventional; Vasculitis | 2006 |
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke | 2006 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment.
Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles | 2007 |
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Prosthesis Failure; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2007 |
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pravastatin; Pyrroles; Sex Characteristics | 2007 |
Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia.
Topics: Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hypercholesterolemia; Insulin-Secreting Cells; Japan; Patient Compliance; Pravastatin; Pyrroles | 2007 |
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Catalase; Dyslipidemias; Erythrocyte Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2006 |
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Artery Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Monocytes; Neopterin; Pravastatin; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Survival Analysis | 2007 |
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.
Topics: Anticholesteremic Agents; Arginine; Atherosclerosis; Atorvastatin; Cross-Sectional Studies; Dinoprost; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2007 |
[The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
Topics: Acute Coronary Syndrome; Aged; Anti-Infective Agents; Atorvastatin; Biomarkers; Calgranulin A; Calgranulin B; Case-Control Studies; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Probability; Pyrroles; Reference Values; Risk Assessment; Survival Rate; Thrombolytic Therapy; Treatment Outcome | 2008 |
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Atrial Fibrillation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.
Topics: Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Treatment Outcome | 2008 |
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides | 2008 |
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Cholesterol; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-18; Interleukin-6; Male; Middle Aged; Pravastatin; Probability; Prospective Studies; Pyrroles; Simvastatin; Triglycerides; Tunica Intima; Ultrasonography | 2008 |
Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Topics: Aged; Atorvastatin; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Topics: Adipokines; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Cross-Over Studies; Female; Glucose Intolerance; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Pravastatin; Pyrroles | 2008 |
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Male; Middle Aged; Oxidative Stress; Phospholipids; Pravastatin; Pyrroles; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2008 |
Use of lipid-modulating drugs in complicated course of coronary heart disease.
Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation.
Topics: Adult; Aged; Atorvastatin; Cross-Sectional Studies; Down-Regulation; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin alpha4; Leukocyte Count; Male; Middle Aged; Monocytes; Pravastatin; Pyrroles; Receptors, IgG; Up-Regulation | 2008 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Pravastatin; Pyrroles; Treatment Outcome | 2008 |
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Cross-Over Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Leukocytes; Male; Pravastatin; Pyrroles; Quinolines; rac1 GTP-Binding Protein; ras Proteins; Rats; Rats, Inbred WKY; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2009 |
Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Count; Cells, Cultured; Cholesterol; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Stem Cells; Telomere | 2009 |
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2008 |
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Seasons | 2009 |
Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; MicroRNAs; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Single-Blind Method; Statistics as Topic; Stem Cells | 2009 |
Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2009 |
Identification of genetic variants associated with response to statin therapy.
Topics: Acute Coronary Syndrome; Apolipoproteins E; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Cholesterol, LDL; Haplotypes; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Phenotype; Polymorphism, Genetic; Practice Guidelines as Topic; Pravastatin; Pyrroles; Treatment Outcome | 2009 |
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2009 |
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles | 2009 |
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin | 2008 |
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke | 2009 |
[Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Ticlopidine; Time; Treatment Outcome; Young Adult | 2009 |
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Genome-wide association of lipid-lowering response to statins in combined study populations.
Topics: Adult; Aged; Atorvastatin; Bayes Theorem; Cholesterol; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2010 |
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Observation; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Factors; Triglycerides | 2010 |
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Proportional Hazards Models; Pyrroles; Risk Factors; Thrombolytic Therapy; Treatment Outcome | 2010 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Neopterin; Pravastatin; Proportional Hazards Models; Pyrroles; Sensitivity and Specificity; Treatment Outcome | 2011 |
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease.
Topics: Aged; Analysis of Variance; Angiogenic Proteins; Angiopoietin-2; Atorvastatin; Biomarkers; Coronary Artery Disease; Down-Regulation; Female; Hepatocyte Growth Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Leptin; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.
Topics: Adult; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Liver; Male; Metabolic Clearance Rate; Midazolam; Organic Anion Transporters; Pravastatin; Pyrroles; Time Factors; Young Adult | 2011 |
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Placenta Growth Factor; Pravastatin; Pregnancy Proteins; Pyrroles; Risk Factors | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocyte Count; Lipids; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Pravastatin; Pyrroles; Regression Analysis; Risk Factors | 2012 |
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors | 2013 |
Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study.
Topics: Adult; Atorvastatin; Blood Glucose; Cholesterol, HDL; Dyslipidemias; Female; Glucose; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postmenopause; Pravastatin; Pyrroles; Young Adult | 2013 |
Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS.
Topics: Administration, Oral; Amlodipine; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Combinations; Drug Stability; Heptanoic Acids; Humans; Isomerism; Linear Models; Pravastatin; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Therapeutic Equivalency | 2013 |
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Atorvastatin; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Genetic Testing; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Markov Chains; Middle Aged; Molecular Targeted Therapy; Pravastatin; Pyrroles; Quality-Adjusted Life Years | 2013 |
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection | 2013 |
The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Atorvastatin; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pravastatin; Pyrroles | 2014 |
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility | 2015 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States | 2015 |
Effect of High-Dose Statin Therapy on Drug-Eluting Stent Strut Coverage.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Prosthesis Design; Republic of Korea; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Remodeling; Wound Healing | 2015 |
A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Triglycerides; United States | 2016 |
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pravastatin; Renal Insufficiency, Chronic; Uric Acid | 2015 |
Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION.
Topics: Aged; Atorvastatin; Exercise Therapy; Exercise Tolerance; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Oxygen Consumption; Pravastatin; Quality of Life; Simvastatin; Stroke Volume; Treatment Outcome; Walk Test | 2016 |
Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease.
Topics: Acute Coronary Syndrome; Atorvastatin; Biomarkers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Troponin I | 2016 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pravastatin; Stroke; Treatment Outcome | 2018 |
The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Atorvastatin; Biomarkers; Colorimetry; Dose-Response Relationship, Drug; Fasting; Female; Follow-Up Studies; Hospitalization; Humans; Immunoturbidimetry; Inflammation; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Retrospective Studies | 2018 |
Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Constriction, Pathologic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2018 |
Comparison and analysis of the therapeutic effect of different statins in the treatment of atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Pravastatin; Simvastatin | 2018 |
Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection.
Topics: Adult; Atorvastatin; Choice Behavior; Decision Support Techniques; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Patient Preference; Pilot Projects; Pravastatin; Precision Medicine; Psychometrics; Rosuvastatin Calcium; Self Efficacy; Simvastatin | 2019 |
Statins Reduce Epicardial Adipose Tissue Attenuation Independent of Lipid Lowering: A Potential Pleiotropic Effect.
Topics: Adipose Tissue; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Organ Size; Pericardium; Pravastatin; Tomography, X-Ray Computed | 2019 |
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Proteins; Pravastatin; Quinolines; Quinoxalines; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2021 |
Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
Topics: Adult; Atorvastatin; Cross-Over Studies; Drug Interactions; Healthy Volunteers; Humans; Pravastatin; Pyridines; Rosuvastatin Calcium; Triazoles | 2022 |
Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Disabled Persons; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Primary Prevention; Proportional Hazards Models; Rosuvastatin Calcium; Simvastatin | 2022 |
334 other study(ies) available for atorvastatin and pravastatin
| Article | Year |
|---|---|
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.
Topics: Amino Acid Sequence; Animals; Anion Transport Proteins; Base Sequence; Biological Transport; Carrier Proteins; Dehydroepiandrosterone Sulfate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Molecular Sequence Data; Pravastatin; Rats; Taurocholic Acid | 1999 |
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Topics: Alleles; Atorvastatin; Biological Transport; Cells, Cultured; Genetic Variation; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver-Specific Organic Anion Transporter 1; Mutagenesis, Site-Directed; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Substrate Specificity; Transfection | 2005 |
Binding thermodynamics of statins to HMG-CoA reductase.
Topics: Atorvastatin; Binding Sites; Calorimetry; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thermodynamics | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
Topics: Animals; Cholesterol, LDL; Cricetinae; Guinea Pigs; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Liver; Male; Mesocricetus; Muscle Cells; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship | 2008 |
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
Topics: Administration, Oral; Animals; Biological Availability; Chemical and Drug Induced Liver Injury; Cholesterol; Crystallography, X-Ray; Dogs; Female; Guinea Pigs; Haplorhini; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver; Models, Molecular; Muscle Cells; Pyrimidines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2008 |
Statins alone are ineffective in cerebral malaria but potentiate artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atorvastatin; Disease Models, Animal; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Malaria, Cerebral; Malaria, Falciparum; Mice; Neuroprotective Agents; Pravastatin; Pyrroles; Simvastatin | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Carbon metabolism-mediated myogenic differentiation.
Topics: | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Unsaturated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tissue Distribution | 1992 |
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1997 |
Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.
Topics: Animals; Apoptosis; Atorvastatin; Carotid Stenosis; Cell Division; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rabbits; Simvastatin | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Protein Prenylation; Pyrroles; Rats; Simvastatin | 1999 |
Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Calcium; Cells, Cultured; Chelating Agents; Dose-Response Relationship, Drug; Drug Interactions; Fura-2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; Muscle Contraction; Muscle, Smooth, Vascular; Phenylephrine; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents | 1999 |
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Base Sequence; Botulinum Toxins; DNA Primers; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phorbol 12,13-Dibutyrate; Pravastatin; Protein Kinase C; Pyridines; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase; Superoxides; Vasodilation | 2000 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
Topics: Apoptosis; Atorvastatin; Cell Survival; Cells, Cultured; Coronary Vessels; Cytokines; Dose-Response Relationship, Drug; Endothelium, Vascular; Fas Ligand Protein; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Glycoproteins; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Reference Values; Sensitivity and Specificity; Simvastatin | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
Statins as a newly recognized type of immunomodulator.
Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Atorvastatin; Endothelium, Vascular; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Lovastatin; Lymphocyte Activation; Macrophages; Monocytes; Nuclear Proteins; Pravastatin; Pyrroles; Saphenous Vein; T-Lymphocytes; Trans-Activators | 2000 |
Statins early in acute coronary syndromes.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Treatment Outcome | 2000 |
Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin.
Topics: Administration, Oral; Animals; Animals, Newborn; Atorvastatin; Blood Pressure; Body Weight; DNA; Heart; Heart Rate; Heart Ventricles; Heptanoic Acids; Mitogen-Activated Protein Kinases; Myocardium; Organ Size; Pravastatin; Proteins; Pyrroles; RNA; Simvastatin; Swine; Water | 2001 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2001 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
Effect of statins on bone mineral density and bone histomorphometry in rodents.
Topics: Animals; Atorvastatin; Bone Density; Bone Development; Bone Resorption; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ovariectomy; Pravastatin; Pyrroles; Radiography; Rats; Rats, Sprague-Dawley; Simvastatin | 2001 |
Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats.
Topics: Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Diltiazem; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Topics: Animals; Aorta; Arteries; Arteriosclerosis; Atorvastatin; Carotid Arteries; Chemokine CCL2; Cholesterol; Coronary Vessels; Down-Regulation; Femoral Artery; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pravastatin; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine | 2001 |
Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines.
Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2001 |
The use over time of statins in coronary patients in an Italian tertiary referral center.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2001 |
Safety and efficacy of atorvastatin in heart transplant recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glucocorticoids; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Prednisone; Pyrroles; Retrospective Studies; Treatment Outcome | 2002 |
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2002 |
Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome | 2001 |
Interaction between ritonavir and statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Ritonavir; Simvastatin | 2002 |
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin | 2002 |
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography | 2002 |
The lower the LDL, the better.
Topics: Academies and Institutes; Atorvastatin; Heptanoic Acids; Human Experimentation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance Coverage; Insurance, Health; Lipoproteins, LDL; Pravastatin; Pyrroles | 2002 |
Zeroing in on how low cholesterol should go.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Risk Factors | 2002 |
Statins regulate alpha2beta1-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells.
Topics: Animals; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemotaxis; Collagen Type I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin alpha2beta1; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rats; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice.
Topics: Aged; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Observer Variation; Patient Compliance; Pravastatin; Probability; Prospective Studies; Pyrroles; Reference Values; Simvastatin; Treatment Failure; Treatment Outcome | 2002 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Models, Economic; Pravastatin; Pyrroles; Simvastatin; United Kingdom | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors | 2003 |
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies | 2003 |
Prevention of nitrate tolerance by long-term treatment with statins.
Topics: Administration, Oral; Animals; Aorta, Thoracic; Atorvastatin; Down-Regulation; Drug Administration Schedule; Drug Tolerance; Guanylate Cyclase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Injections, Subcutaneous; Luminescent Measurements; Male; NADH, NADPH Oxidoreductases; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitroglycerin; Pravastatin; Pyrroles; Rats; Rats, Wistar; Superoxides; Vasodilator Agents | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Glucose; Glucose Tolerance Test; Heptanoic Acids; Injections, Intravenous; Insulin; Insulin Secretion; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Streptozocin; Time Factors | 2003 |
Statin face-off. Surprises from the first head-to-head comparison.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Treatment Outcome; United States | 2003 |
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography | 2003 |
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E | 2003 |
Aggressive lipid-lowering regimen halts CHD progression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
[First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Time Factors; Ultrasonography, Interventional | 2003 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Is there a "best" statin drug?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Toward a role for statins in immunomodulation.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2002 |
High-intensity statin treatment for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Dropouts; Pravastatin; Pyrroles; Risk Factors; Ultrasonography, Interventional | 2004 |
Is Lipitor better than Pravachol?
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2004 |
Intensive statin therapy--a sea change in cardiovascular prevention.
Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
What to do about cholesterol now. Here's the take-home message from startling new research findings.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomedical Research; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2004 |
Lipitor bests Pravachol at certain doses.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention | 2004 |
Cholesterol: low is good. Lower is better. PROVE IT has doctors rethinking how to treat high cholesterol and what's a good target.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values | 2004 |
Cholesterol limbo: How low should the bar go. Ratcheting down LDL to extra-low levels with high-dose statins seems to work wonders.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Reference Values | 2004 |
Clopidogrel-atorvastatin interaction.
Topics: Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Heptanoic Acids; Humans; Platelet Aggregation Inhibitors; Pravastatin; Prodrugs; Pyrroles; Ticlopidine | 2004 |
Believe-it then PROVE-IT.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Reference Values | 2004 |
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
Topics: Adult; Annexin A5; Apoptosis; Atorvastatin; Caspase 3; Caspases; Cholesterol; Enzyme Inhibitors; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2004 |
"Major surprise" in a new study means likely changes in treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values | 2004 |
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate | 2004 |
[Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Ultrasonography, Interventional | 2004 |
[Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography | 2004 |
New LDL goals: even lower?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Secondary Prevention | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Battle of the statins, or how the news media can change patient care.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Media; Practice Patterns, Physicians'; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
[Endothelial dysfunction, inflammation and statins: new evidences].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Circulation; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Interleukin-6; Pravastatin; Pyrroles; Rabbits; Time Factors | 2004 |
[Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Approval; Drugs, Generic; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles | 2004 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
[Lowering of cholesterol. What role is played by the choice of statins?].
Topics: Adult; Age Factors; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Time Factors | 2004 |
How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Pravastatin; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2004 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
What did PROVE-IT prove?
Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results; Thrombolytic Therapy | 2004 |
Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Endothelium, Vascular; Glyburide; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Nitroarginine; Ouabain; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Wistar; Vasodilation | 2005 |
PROVE IT then believe it.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2005 |
Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
Topics: Adolescent; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hyperlipidemias; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Reversal of atherosclerosis with aggressive lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hyperlipidemias; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileal Diseases; Ileum; Indoles; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Ulcer | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
Adverse events with concomitant amiodarone and statin therapy.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Amiodarone; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
[The PROVE IT-TIMI-22 study or the biter being bit].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles | 2005 |
Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.
Topics: Apoptosis; Atorvastatin; Avidin; Biotin; Cell Line; Cell Separation; Cells, Cultured; Drug Industry; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia; Microscopy, Fluorescence; Necrosis; Pharmaceutical Preparations; Pravastatin; Propidium; Pyridines; Pyrroles; Simvastatin; Time Factors | 2005 |
Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial.
Topics: Atorvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk | 2005 |
Acute onset and worsening of diabetes concurrent with administration of statins.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles | 2005 |
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Animals; Atorvastatin; Cell Culture Techniques; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Mice; Pioglitazone; PPAR gamma; Pravastatin; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Thiazolidinediones | 2005 |
Statin use after acute myocardial infarction: a nationwide study in Denmark.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Atorvastatin; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Pravastatin; Pyrroles; Registries; Sex Distribution; Simvastatin | 2005 |
In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells.
Topics: Atorvastatin; Cell Proliferation; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Mitogens; Pravastatin; Pyrroles; Simvastatin | 2005 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies?
Topics: Atorvastatin; Coronary Artery Disease; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Outcome Assessment, Health Care; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Not all statins interfere with clopidogrel during antiplatelet therapy.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2005 |
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine; Time Factors; Wound Healing | 2005 |
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Utilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Thrombolytic Therapy | 2005 |
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors | 2005 |
New light on statin side effects. What recent research on the cholesterol drugs means to you.
Topics: Atorvastatin; Biomedical Research; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Differences between statins on clinical endpoints: a population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome | 2005 |
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Creatine Kinase; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States | 2005 |
Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages.
Topics: Animals; Atorvastatin; Cell Proliferation; Concanavalin A; Heptanoic Acids; Lectins; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microspheres; Mitogens; Phagocytosis; Pravastatin; Pyrroles; Simvastatin; Spleen | 2006 |
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
[How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors | 2005 |
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Infections; Male; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Safety of statins when response is carefully monitored: a study of 336 heart recipients.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Middle Aged; Overweight; Pravastatin; Pyrroles; Retrospective Studies; Safety | 2005 |
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
Topics: Animals; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Pravastatin; Pyrroles; Serotonin; Simvastatin; Swine; Time Factors; Vasoconstriction | 2006 |
Muscle symptoms associated with statins: a series of twenty patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin | 2006 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2006 |
Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carbohydrate Metabolism; Diabetes Mellitus; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Pravastatin; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
Effect of statin treatment on coronary collateral development in patients with diabetes mellitus.
Topics: Angina Pectoris; Atorvastatin; Cholesterol, LDL; Collateral Circulation; Coronary Angiography; Coronary Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Topics: Adult; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Cells, Cultured; DNA Fragmentation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Myocytes, Cardiac; Neoplasm Proteins; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2006 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies | 2006 |
Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells.
Topics: Animals; Aorta; Atorvastatin; Cells, Cultured; Endothelial Cells; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Pyridines; Pyrroles; Quinolines; RNA, Messenger; Swine | 2006 |
Effects of preoperative statin therapy on cytokines after cardiac surgery.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Heart Arrest, Induced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Interleukin-6; Male; Postoperative Complications; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome.
Topics: Atorvastatin; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Organ Failure; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Survival Rate | 2006 |
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Annexins; Anticholesteremic Agents; Atorvastatin; Biomarkers; Calcium Channels, L-Type; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Receptors, LDL; Simvastatin | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2006 |
[For coronary disease patients is certain: the lower the LDL the better].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Odds Ratio; Pravastatin; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 2006 |
Clopidogrel-statin interaction: a mountain or a mole hill?
Topics: Atorvastatin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine | 2006 |
Pleiotropic effects of statins and early benefit in the PROVE IT-TIMI-22 study.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Endpoint Determination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Toxicity of statins on rat skeletal muscle mitochondria.
Topics: Animals; Apoptosis; Atorvastatin; Cytochromes c; DNA Fragmentation; Fatty Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potentials; Mitochondria, Muscle; Mitochondrial Membranes; Muscle, Skeletal; Oxygen; Pravastatin; Pyridines; Pyrroles; Rats; Simvastatin | 2006 |
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Topics: Acetylcholine; Animals; Apoptosis; Atorvastatin; Caspase 3; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Nitroprusside; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Ventricular Pressure | 2006 |
Impact of high dose statin trials on hospital prescribers.
Topics: Aged; Atorvastatin; Cohort Studies; Coronary Disease; Databases, Factual; Drug Prescriptions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Patient Discharge; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinoma, Hepatocellular; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Etoposide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Morpholines; Phosphorylation; Pravastatin; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2006 |
The MEGA study.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2007 |
Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; Simvastatin; Sterol Regulatory Element Binding Protein 1 | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Statin therapy and the elderly: SAGE advice?
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Pyrroles | 2007 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Topics: Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blotting, Western; Cell Line; Cell Proliferation; Cell Survival; Constitutive Androstane Receptor; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Endothelial Cells; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Glucocorticoid; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saphenous Vein; Transcription Factors; Up-Regulation | 2007 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Physiogenomic association of statin-related myalgia to serotonin receptors.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Brain; Heptanoic Acids; Lactones; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Pravastatin; Pyrroles; Simvastatin | 2007 |
Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Caspase 3; Cell Line; Clofibrate; DNA Fragmentation; Drug Synergism; Enzyme Activation; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Pravastatin; Pyridines; Pyrroles | 2007 |
On the factors modulating the effect of statins on malignant cell proliferation.
Topics: Annexin A5; Atorvastatin; Cell Division; Cell Line, Tumor; DNA Fragmentation; DNA, Neoplasm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; K562 Cells; Kinetics; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 2007 |
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro.
Topics: Adult; Apoptosis; Atorvastatin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Middle Aged; Phagocytes; Phagocytosis; Pravastatin; Pyrroles; Simvastatin | 2008 |
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
Topics: Adult; Animals; Atorvastatin; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; T-Lymphocytes, Regulatory; Up-Regulation | 2008 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin | 2007 |
Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases, Factual; Drug Administration Schedule; Drug Prescriptions; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Norway; Patient Selection; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Sex Factors; Simvastatin; Tablets | 2007 |
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Infant; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Lowering LDL-C for optimal protection in high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Guideline Adherence; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Assessment | 2008 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
Topics: Acids; Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Lactones; Microscopy, Fluorescence; Molecular Structure; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Satellite Cells, Skeletal Muscle; Simvastatin; Structure-Activity Relationship | 2008 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Topics: 3T3-L1 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; ADP Ribose Transferases; Amides; Animals; Atorvastatin; Botulinum Toxins; Dose-Response Relationship, Drug; Glucose; Glucose Transporter Type 4; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Receptor Substrate Proteins; Mice; Phosphorylation; Polyisoprenyl Phosphates; Pravastatin; Protein Kinase Inhibitors; Protein Prenylation; Protein Transport; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; rab4 GTP-Binding Proteins; Receptor, Insulin; rho GTP-Binding Proteins; rho-Associated Kinases; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction | 2008 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Coronary Angiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoprotein(a); Male; Malondialdehyde; Middle Aged; Oxidative Stress; Phospholipids; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2008 |
Lipid management: considerations in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Triglycerides | 2008 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2008 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects?
Topics: Atorvastatin; Cells, Cultured; Chemotactic Factors; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Infiltration; Neutrophils; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; rhoA GTP-Binding Protein; Simvastatin | 2009 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies | 2008 |
The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Lipids; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Young Adult | 2008 |
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides | 2008 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Topics: Animals; Atorvastatin; Disease Models, Animal; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Preoperative statin use and infection after cardiac surgery: a cohort study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemoprevention; Cohort Studies; Female; Heptanoic Acids; Hospitals, University; Humans; Immunologic Factors; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Surgical Wound Infection; Thoracic Surgery; Treatment Outcome | 2009 |
Potentiated cytotoxic effects of statins and ajoene in murine melanoma cells.
Topics: Animals; Apoptosis; Atorvastatin; Cell Line, Tumor; Disulfides; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanocytes; Melanoma, Experimental; Mevalonic Acid; Mice; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Sulfoxides; Terpenes | 2009 |
Seasonal variation in lipids: should we consider it more?
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Seasons | 2009 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |
Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Risk Factors; Triglycerides | 2010 |
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors | 2009 |
Letter by Superko and King regarding article, "Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals".
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Genetic Predisposition to Disease; Goals; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Male; Middle Aged; Mutation, Missense; Patient Selection; Pravastatin; Pyrroles; Risk | 2010 |
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.
Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures | 2010 |
Statins in acute coronary syndromes and genetic insight.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
Pravastatin treatment before coronary artery bypass grafting for reduction of postoperative atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
Pitavastatin: the newest HMG-CoA reductase inhibitor.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin | 2010 |
Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression.
Topics: Aspirin; Atorvastatin; Case-Control Studies; Confidence Intervals; Cytokines; Depressive Disorder, Major; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Middle Aged; Models, Psychological; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2010 |
Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway.
Topics: Animals; Atorvastatin; Catalase; Cellular Senescence; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sirtuin 1; Umbilical Veins | 2010 |
Differential effects of statins on endogenous H2S formation in perivascular adipose tissue.
Topics: Adipose Tissue; Animals; Aorta, Thoracic; Atorvastatin; Cholesterol; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; KATP Channels; Liver; Male; Mitochondria, Liver; Oxidation-Reduction; Potassium Channel Blockers; Pravastatin; Pyrroles; Quinone Reductases; Rats; Rats, Wistar; Sulfides; Triglycerides; Ubiquinone; Vasoconstrictor Agents; Vasodilation | 2011 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin.
Topics: Alanine Transaminase; Alkaline Phosphatase; Atorvastatin; Cytochrome P-450 CYP3A; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Middle Aged; Pravastatin; Pyrroles | 2010 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions.
Topics: Atorvastatin; Blood Platelets; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; P-Selectin; Perfusion; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Regional Blood Flow; Stress, Mechanical; Thrombin; Thromboplastin; Thrombosis; Time Factors; von Willebrand Factor | 2011 |
A novel use of oxidative coupling reactions for determination of some statins (cholesterol-lowering drugs) in pharmaceutical formulations.
Topics: Atorvastatin; Chemistry, Pharmaceutical; Dosage Forms; Excipients; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Molecular Structure; Oxidation-Reduction; Oxidative Coupling; Pravastatin; Pyrroles; Spectrophotometry | 2011 |
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome | 2011 |
Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Electronic Health Records; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Primary Prevention; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Thailand | 2011 |
Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells.
Topics: Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pravastatin; Pyrroles; Simvastatin; Tetradecanoylphorbol Acetate; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Umbilical Veins | 2011 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.
Topics: Animals; Atorvastatin; Cholesterol; Crystallization; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Microscopy, Electron, Scanning; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2011 |
[Retention behavior of statins in microemulsion liquid chromatography].
Topics: Atorvastatin; Chromatography, Liquid; Emulsions; Heptanoic Acids; Lovastatin; Models, Chemical; Pravastatin; Pyrroles; Simvastatin | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites.
Topics: Adipokines; Adipose Tissue; Animals; Atorvastatin; Biomarkers; Blood Glucose; Calcifediol; Calcitriol; Cholecalciferol; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Pravastatin; Pyrroles; Rats; Rats, Wistar; Time Factors | 2011 |
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells.
Topics: Apoptosis; Atorvastatin; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Genetic Pleiotropy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pulmonary Artery; Pyrroles; Simvastatin | 2011 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; NF-kappa B; Pravastatin; Pyrroles; Simvastatin | 2011 |
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Female; Galectin 3; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin.
Topics: Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Retrospective Studies; Secondary Prevention; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome | 2011 |
Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition.
Topics: Adult; Aspirin; Atorvastatin; Blood Platelets; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2012 |
Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle Cells; Muscle Strength; Muscle, Skeletal; Organ Size; Oxygen Consumption; Physical Conditioning, Animal; Physical Endurance; Pravastatin; Pyrroles; Ubiquinone | 2012 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB.
Topics: Animals; Atorvastatin; Calcium; Cell Line; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Mice; Microglia; Phosphorylation; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Signal Transduction; Simvastatin; Up-Regulation | 2012 |
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies.
Topics: Atorvastatin; Cell Compartmentation; Chemokine CXCL1; Chemokines; E-Selectin; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1beta; Intracellular Space; Multivesicular Bodies; Pravastatin; Prenylation; Pyrroles; Simvastatin; Solubility; Subcellular Fractions; Tetraspanin 30 | 2012 |
The evaluation of analgesic effects of simvastatin, pravastatin and atorvastatin in hot plate test.
Topics: Analgesics; Animals; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred BALB C; Naloxone; NG-Nitroarginine Methyl Ester; Pravastatin; Pyrroles; Simvastatin | 2012 |
Evaluation of transporter-mediated hepatic uptake in a non-radioactive high-throughput assay: a study of kinetics, species difference and plasma protein effect.
Topics: Animals; Atorvastatin; Biological Assay; Biological Transport; Blood Proteins; Cells, Cultured; Cryopreservation; Estrone; Female; Hepatocytes; Heptanoic Acids; High-Throughput Screening Assays; Humans; Kinetics; Liver; Male; Metformin; Organic Anion Transporters; Pravastatin; Pyrroles; Radioactivity; Reproducibility of Results; Species Specificity; Time Factors | 2013 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins B; Atorvastatin; Blood-Brain Barrier; Brain; Diet, High-Fat; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ibuprofen; Immunoglobulin G; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles | 2012 |
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Comorbidity; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polypharmacy; Pravastatin; Propensity Score; Proportional Hazards Models; Pyrroles; Registries; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
Antilipid agents may provide allergy protection.
Topics: Animals; Asthma; Atorvastatin; Bronchial Hyperreactivity; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypersensitivity; Pravastatin; Pyrroles | 2013 |
Effect of oral administration with pravastatin and atorvastatin on airway hyperresponsiveness and allergic reactions in asthmatic mice.
Topics: Administration, Oral; Animals; Asthma; Atorvastatin; Bronchial Hyperreactivity; Cytokines; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypersensitivity; Immunoglobulin G; Mice; Mice, Inbred BALB C; Ovalbumin; Pravastatin; Pyrroles; Rats, Sprague-Dawley; Th1 Cells | 2013 |
Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Blood Platelets; Calcium; Collagen; Cyclooxygenase 1; Drug Combinations; Drug Synergism; Heptanoic Acids; Humans; Mitogen-Activated Protein Kinases; Phospholipase A2 Inhibitors; Phospholipases A2; Phosphorylation; Platelet Aggregation; Pravastatin; Pyrroles; Simvastatin; Thromboxane A2; Thromboxane-A Synthase | 2013 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Statins for treating stable angina: can statins improve the plaque morphology and angina?
Topics: Angina Pectoris; Angina, Stable; Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2013 |
Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Hepacivirus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proline; Protease Inhibitors; Pyrroles; Treatment Outcome; Young Adult | 2013 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
Topics: Animals; Atorvastatin; Biomarkers; Endotoxins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin | 2013 |
Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory.
Topics: Animals; Atorvastatin; Body Weight; Cholesterol; Cognition; Discrimination, Psychological; Heptanoic Acids; Male; Memory; Pravastatin; Pyrroles; Rats; Reversal Learning; Time Factors | 2013 |
Long-term use of statins reduces the risk of hospitalization for dementia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Dementia; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Italy; Logistic Models; Male; Middle Aged; Pravastatin; Pyrroles; Risk; Simvastatin; Time Factors | 2013 |
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Biological Availability; Heptanoic Acids; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Knockout; Middle Aged; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pravastatin; Pyrroles; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Tissue Distribution; Young Adult | 2014 |
Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Cells, Cultured; Chemokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Inflammation Mediators; Leukocytes, Mononuclear; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2014 |
Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Female; Gonadal Steroid Hormones; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Networks and Pathways; Ovary; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Theca Cells | 2014 |
Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
Topics: Adult; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Socioeconomic Factors | 2014 |
Daily administration of atorvastatin and simvastatin for one week improves cardiac function in type 1 diabetic rats.
Topics: Animals; Atorvastatin; Blood Glucose; Cardiac Output; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Heart; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Ventricular Function, Left | 2014 |
Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Inhalation Exposure; Lung; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2014 |
Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Bilirubin; Biological Transport; Cell Culture Techniques; Cells, Cultured; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Pyrimidines; Pyrroles; Rats; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statins upregulate cystathionine γ-lyase transcription and H2S generation via activating Akt signaling in macrophage.
Topics: Animals; Atorvastatin; Cell Line; Cystathionine gamma-Lyase; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Macrophages; Mice; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Signal Transduction; Up-Regulation | 2014 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?
Topics: Atorvastatin; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin | 2015 |
Statins impair survival of primary human mesenchymal progenitor cells via mevalonate depletion, NF-κB signaling, and Bnip3.
Topics: Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Kinase; Membrane Proteins; Mesenchymal Stem Cells; Mevalonic Acid; NF-kappa B; Pravastatin; Proto-Oncogene Proteins; Signal Transduction; Simvastatin; Time Factors; Transcription Factor RelA | 2015 |
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.
Topics: Anti-Retroviral Agents; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; HIV Infections; HIV-1; Humans; Immunologic Factors; Interferon-gamma; Lymphocyte Activation; Pravastatin; Pyrroles; Retrospective Studies; T-Lymphocyte Subsets; T-Lymphocytes | 2014 |
Green analytical method development for statin analysis.
Topics: Acetonitriles; Atorvastatin; Chromatography, High Pressure Liquid; Ethanol; Fatty Acids, Monounsaturated; Fluvastatin; Green Chemistry Technology; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Pyrroles; Solubility; Solvents | 2015 |
Indirect protein quantification of drug-transforming enzymes using peptide group-specific immunoaffinity enrichment and mass spectrometry.
Topics: Amino Acid Sequence; Antibodies; Antibody Affinity; Aryl Hydrocarbon Hydroxylases; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cells, Cultured; Chromatography, Liquid; Cytochrome P-450 CYP3A; Epitopes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Spectrometry; Peptides; Pravastatin; Primary Cell Culture; Sequence Homology, Amino Acid | 2015 |
Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm.
Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Bacterial Adhesion; Biofilms; Drug Repositioning; Enterococcus faecalis; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Pravastatin; Pseudomonas aeruginosa; Simvastatin; Vancomycin | 2015 |
Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Blood Glucose; Cardiotonic Agents; Catalase; Cholesterol; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoproterenol; Male; Myocardial Infarction; Myocardium; Necrosis; Pravastatin; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Superoxide Dismutase; Triglycerides | 2015 |
Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Patterns, Physicians'; Pravastatin; Qatar | 2015 |
The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it.
Topics: Adult; Aged; Apolipoprotein C-III; Atorvastatin; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Dyslipidemias; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin | 2015 |
Statins up-regulate SmgGDS through β1-integrin/Akt1 pathway in endothelial cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Atorvastatin; Cells, Cultured; Cytoskeletal Proteins; Endothelial Cells; Gene Expression Regulation; Guanine Nucleotide Exchange Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin beta1; Mice; Mice, Inbred C57BL; Phosphorylation; Pravastatin; Proto-Oncogene Proteins c-akt; Signal Transduction; Up-Regulation | 2016 |
Different effects of statins on induction of diabetes mellitus: an experimental study.
Topics: Atorvastatin; Cell Cycle; Cell Survival; Cells, Cultured; Diabetes Mellitus; Dose-Response Relationship, Drug; Glucose; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Muscle, Skeletal; Pravastatin; Quinolines; Rosuvastatin Calcium; Signal Transduction; Structure-Activity Relationship | 2015 |
Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk Factors; Simvastatin; Sweden | 2016 |
Dual Incorporation of the in vitro Data (IC50) and in vivo (Cmax) Data for the Prediction of Area Under the Curve (AUC) for Statins using Regression Models Developed for Either Pravastatin or Simvastatin.
Topics: Area Under Curve; Atorvastatin; Drug Design; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; Linear Models; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2016 |
Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort Study.
Topics: Aged; Anticoagulants; Atorvastatin; Atrial Fibrillation; Drug Interactions; Electronic Health Records; Female; Gastrointestinal Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Software; Tertiary Care Centers; Warfarin | 2016 |
Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Topics: Aged; Aged, 80 and over; Atorvastatin; Clinical Trials as Topic; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Interrupted Time Series Analysis; Lovastatin; Male; Nova Scotia; Pravastatin; Prescription Drugs; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2016 |
The Different Effects of Atorvastatin and Pravastatin on Cell Death and PARP Activity in Pancreatic NIT-1 Cells.
Topics: Animals; Atorvastatin; Autophagy; Cell Cycle; Cell Death; Cell Line; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Interleukin-6; Mice; Mitochondria; Oxidative Stress; Pancreas; Poly (ADP-Ribose) Polymerase-1; Pravastatin; Reactive Oxygen Species; Signal Transduction | 2016 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.
Topics: Animals; Anticholesteremic Agents; Arthritis; Atorvastatin; Docosahexaenoic Acids; Inflammation; Leukocytes; Male; Mice; Mice, Inbred C57BL; Pravastatin | 2017 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
Statin and Its Association With Delirium in the Medical ICU.
Topics: Aged; Atorvastatin; Delirium; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive Care Units; Male; Middle Aged; Odds Ratio; Pravastatin; Propensity Score; Reproducibility of Results; Retrospective Studies; Simvastatin | 2017 |
Polypharmacy and sun exposure: Implications for mitochondrial DNA deletions in skin.
Topics: Aged; Allopurinol; Atorvastatin; Bisoprolol; Cholesterol; DNA Damage; DNA, Mitochondrial; Gene Deletion; Humans; Mitochondria; Perindopril; Pravastatin; Real-Time Polymerase Chain Reaction; Skin; Ubiquinone; Ultraviolet Rays | 2017 |
Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Topics: Asian People; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbamates; Computer Simulation; Gene Frequency; Genotype; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Models, Biological; Neoplasm Proteins; Pharmacogenomic Variants; Phenotype; Piperidines; Pravastatin; Quinolines; Rosuvastatin Calcium; White People | 2018 |
Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells.
Topics: Atorvastatin; Cells, Cultured; Humans; Lovastatin; PCSK9 Inhibitors; Pravastatin; Proprotein Convertase 9; Receptors, LDL; Structure-Activity Relationship | 2017 |
Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat β-Cells. Direct Effect of Oxidative Stress.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mitochondria; Oxidative Stress; Pravastatin; Rats; Reactive Oxygen Species | 2017 |
Atorvastatin affects negatively respiratory function of isolated endothelial mitochondria.
Topics: Atorvastatin; Calcium; Electron Transport; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Oxidative Phosphorylation; Oxygen Consumption; Pravastatin; Reactive Oxygen Species; Respiration | 2018 |
Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures.
Topics: Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry; Valsartan | 2017 |
Atorvastatin-Induced Dermatomyositis: Resolution With Change in Statin?
Topics: Antibodies, Antinuclear; Atorvastatin; Autoantibodies; Autoimmunity; Biopsy; Coronary Artery Disease; Dermatomyositis; Diagnosis, Differential; Drug Substitution; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscle Weakness; Pravastatin; Serologic Tests; Skin; Treatment Outcome | 2018 |
Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Topics: Adult; Aged; Atorvastatin; Depression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Propensity Score; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Suicide, Attempted; United States | 2018 |
Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes.
Topics: Animals; Atorvastatin; Cell Line; Cell Survival; Cholesterol, LDL; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mitochondria, Heart; Myocytes, Cardiac; Pravastatin; Proto-Oncogene Proteins c-akt; rhoA GTP-Binding Protein; Signal Transduction; TOR Serine-Threonine Kinases; Transcriptome; Vinculin | 2019 |
Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.
Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Primary Prevention; Risk Assessment; Rosuvastatin Calcium; Sex Factors; Simvastatin | 2019 |
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells.
Topics: Atorvastatin; Cell Line; Cell Movement; Cell Proliferation; Endometriosis; Endometrium; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Stromal Cells | 2019 |
The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation.
Topics: Animals; Atorvastatin; Biological Transport; Cells, Cultured; Hepatocytes; Kinetics; Liver; Membrane Transport Proteins; Metabolic Clearance Rate; Organic Anion Transporters; Pravastatin; Protein Binding; Quinolines; Rats; Rosuvastatin Calcium | 2019 |
Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Protective Factors; Rectal Neoplasms; Retrospective Studies; Simvastatin; Survival Rate; Sweden | 2019 |
Association Between Statin Use and Sex Hormone in the Multi-Ethnic Study of Atherosclerosis Cohort.
Topics: Aged; Aged, 80 and over; Asian; Atorvastatin; Black or African American; Case-Control Studies; Dehydroepiandrosterone; Estradiol; Female; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Multivariate Analysis; Pravastatin; Sex Hormone-Binding Globulin; Simvastatin; Testosterone; United States; White People | 2019 |
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Topics: Amlodipine; Anti-HIV Agents; Atorvastatin; Chromatography, High Pressure Liquid; Drug Interactions; HIV Infections; Humans; Linear Models; Metoprolol; Pravastatin; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Tandem Mass Spectrometry | 2019 |
Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring.
Topics: Atorvastatin; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Drug Monitoring; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Lovastatin; Medication Adherence; Pravastatin; Quality Control; Reference Standards; Tandem Mass Spectrometry | 2020 |
The Influence of Statins on the Aerobic Metabolism of Endothelial Cells.
Topics: Atorvastatin; Cell Line; Electron Transport Complex III; Electron Transport Complex IV; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitochondria; Oxygen Consumption; Pravastatin; Reactive Oxygen Species | 2020 |
Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.
Topics: Animals; Atorvastatin; Caspase 3; Caspase 7; Cell Line; Cell Survival; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Myoblasts; Pravastatin; Protective Agents; Rats; Resveratrol; Signal Transduction; Simvastatin | 2020 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells.
Topics: Anticholesteremic Agents; Antioxidants; Atorvastatin; Cell Line; Cells, Cultured; Endothelial Cells; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitochondria; Nicotinamide N-Methyltransferase; Nitric Oxide; Pravastatin; Pyrroles; Reactive Oxygen Species | 2021 |
Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Lung Neoplasms; Pravastatin; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2021 |
Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs.
Topics: Animals; Atorvastatin; Dogs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mineral Oil; Pravastatin; Pyrroles | 2021 |
Assessing the Interactions of Statins with Human Adenylate Kinase Isoenzyme 1: Fluorescence and Enzyme Kinetic Studies.
Topics: Adenylate Kinase; Amino Acid Sequence; Atorvastatin; Circular Dichroism; Fluvastatin; Geobacillus stearothermophilus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; Isoenzymes; Kinetics; Ligands; Molecular Docking Simulation; Pravastatin; Protein Binding; Recombinant Proteins; Rosuvastatin Calcium; Sequence Alignment; Simvastatin; Spectrometry, Fluorescence; Spectrophotometry; Static Electricity; Temperature | 2021 |
Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study.
Topics: Aged; Atorvastatin; Cross-Sectional Studies; Diabetes Mellitus; Glucose; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Prediabetic State; Rosuvastatin Calcium; Simvastatin; Spain | 2022 |
Statins No Longer Contraindicated in Pregnancy.
Topics: Atorvastatin; Cardiovascular Diseases; Contraindications; Drug Approval; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pregnancy; United States; United States Food and Drug Administration | 2021 |
Hair analysis as a new tool to monitor adherence to long-term therapy to statins.
Topics: Atorvastatin; Cholesterol; Hair Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin | 2023 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
Atorvastatin Exerts More Selective Inhibitory Effects on hMCT2 than on hMCT1 and hMCT4.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Protein Isoforms; Rosuvastatin Calcium; Simvastatin | 2023 |
Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 CYP2C9; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Neoplasm Proteins; Pharmacogenetics; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2023 |